Neuron UAE

Belkins
Reliability, Loyalty and Expertise has been the core foundation upon which Neuron has established itself as one of the leading Third Party Administrators (TPAs) in the MENA region. Delivering unmatched services and business solutions, Neuron has carved a niche for itself as a TPA amongst regional and international insurance companies and several multi-national self-funded organizations. Moreover, our cordial relationship in the healthcare sector over a decade has extended our provider network, both in local and international grounds, providing immense sense of security to our members during travel.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET

ASTRAZENECA AND R-PHARM SIGN AN AGREEMENT TO COOPERATE ON COVID-19 VACCINE DEVELOPMENT

AstraZeneca | December 22, 2020

news image

The Russian Direct Investment Fund (RDIF, Russia's sovereign abundance reserve), The Gamaleya National Center, AstraZeneca and R-Pharm have consented to an arrangement focused on the turn of events and usage of a clinical exploration program to survey the immunogenicity and security of the consolidated utilization of one of the segments of the Sputnik V immunization created by the Gamaleya Center, and one of the segments of the AZD1222 antibody, created by AstraZeneca and the University of O...

Read More

ASTRAZENECA SPINOFF VIELA BIO SCORED ITS FIRST FDA NOD. CAN IT FACE DOWN HEAVYWEIGHT RIVALS?

Fiercepharma | June 16, 2020

news image

Two years after launching, AstraZeneca spinoff Viela Bio has its first FDA approval in Uplinza following Friday's nod to treat certain patients with neuromyelitis optica spectrum disorder. Analysts expect that the medicine, which won approval to treat patients who are anti-AQP4 antibody positive, can generate $586 million by 2026, according to Evaluate. But the competitive landscape could pose a challenge for the biotech's first launch. Doctors could prescribe Roche’s Rituxan or it...

Read More

PHRMA, BIO CAMPAIGN CHAMPIONS MEMBERS' DETERMINATION TO BEAT COVID-19

FiercePharma | March 23, 2020

news image

Together is better, especially when it comes to fighting COVID-19. That’s how pharma and biotech companies are working—and the Pharmaceutical Research and Manufacturers of America (PhRMA) and Biotechnology Industry Organization (BIO) trade groups want everyone to know. They've launched a co-sponsored print and digital campaign titled “Our Commitment to Beat Coronavirus” that lays out the six key steps biopharma companies are taking to combat the novel coronavirus. Tho...

Read More

RAPID NHS RESPONSE TEAMS TO HELP OLDER PEOPLE AT HOME

PharmaTimes | January 28, 2020

news image

The NHS has announced new “expert rapid response teams” in order to help support older people to remain well at home and avoid hospital admissions. New plans outlined by the health service say that the teams will be able to be on hand within two hours, as part of the NHS’ Long Term Plan to support England’s ageing population and those with complex needs. Backed by £14 million of investment, local health service and council teams will begin the roll out of the servic...

Read More

PHARMACY MARKET

AstraZeneca | December 22, 2020

news image

ASTRAZENECA AND R-PHARM SIGN AN AGREEMENT TO COOPERATE ON COVID-19 VACCINE DEVELOPMENT

The Russian Direct Investment Fund (RDIF, Russia's sovereign abundance reserve), The Gamaleya National Center, AstraZeneca and R-Pharm have consented to an arrangement focused on the turn of events and usage of a clinical exploration program to survey the immunogenicity and security of the consolidated utilization of one of the segments of the Sputnik V immunization created by the Gamaleya Center, and one of the segments of the AZD1222 antibody, created by AstraZeneca and the University of O...

Read More

Fiercepharma | June 16, 2020

news image

ASTRAZENECA SPINOFF VIELA BIO SCORED ITS FIRST FDA NOD. CAN IT FACE DOWN HEAVYWEIGHT RIVALS?

Two years after launching, AstraZeneca spinoff Viela Bio has its first FDA approval in Uplinza following Friday's nod to treat certain patients with neuromyelitis optica spectrum disorder. Analysts expect that the medicine, which won approval to treat patients who are anti-AQP4 antibody positive, can generate $586 million by 2026, according to Evaluate. But the competitive landscape could pose a challenge for the biotech's first launch. Doctors could prescribe Roche’s Rituxan or it...

Read More

FiercePharma | March 23, 2020

news image

PHRMA, BIO CAMPAIGN CHAMPIONS MEMBERS' DETERMINATION TO BEAT COVID-19

Together is better, especially when it comes to fighting COVID-19. That’s how pharma and biotech companies are working—and the Pharmaceutical Research and Manufacturers of America (PhRMA) and Biotechnology Industry Organization (BIO) trade groups want everyone to know. They've launched a co-sponsored print and digital campaign titled “Our Commitment to Beat Coronavirus” that lays out the six key steps biopharma companies are taking to combat the novel coronavirus. Tho...

Read More

PharmaTimes | January 28, 2020

news image

RAPID NHS RESPONSE TEAMS TO HELP OLDER PEOPLE AT HOME

The NHS has announced new “expert rapid response teams” in order to help support older people to remain well at home and avoid hospital admissions. New plans outlined by the health service say that the teams will be able to be on hand within two hours, as part of the NHS’ Long Term Plan to support England’s ageing population and those with complex needs. Backed by £14 million of investment, local health service and council teams will begin the roll out of the servic...

Read More